Cookies

Like most websites The Ophthalmologist uses cookies. In order to deliver a personalized, responsive service and to improve the site, we remember and store information about how you use it. Learn more.
Subspecialties Basic & Translational Research, Retina

Age-related Methylation Degeneration

Patients with neovascular AMD rely on intravitreal injections of anti-VEGF – an onerous treatment which slows, but does not prevent, vision loss. Those with the non-neovascular form are similarly poorly served: they have no therapeutic options beyond vitamin supplements, and in the UK national health service, they are not even regularly monitored. Indeed, patients with non-neovascular AMD – despite representing the largest AMD patient group – have seen no significant change in their prognosis for decades. Yet interruption of the disease in this group of patients – as well as being desirable in itself – would avoid the undesirable treatments and unavoidable consequences associated with progression to neovascular AMD. Surely the early/intermediate AMD stages deserve more attention?

Read the full article now

Log in or register to read this article in full and gain access to The Ophthalmologist’s entire content archive. It’s FREE and always will be!

Login

Or register now - it’s free and always will be!

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine
Register

Or Login via Social Media

By clicking on any of the above social media links, you are agreeing to our Privacy Notice.

Register to The Ophthalmologist

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:

  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Ophthalmologist magazine

Register